title: Devices and topical agents for rosacea management.
abstract: Rosacea is a chronic inflammatory disease that predominantly affects facial skin in light-skinned individuals and can be divided into 4 subtypes. Patients can display signs of more than 1 subtype. Diffuse facial erythema is a common finding in rosacea patients and can lead to persistent erythema. Although there is no cure for rosacea, reduction of signs and symptoms can be achieved via various treatment modalities. This article reviews devices and topical agents currently available for the management of rosacea.
authors.forename: Yasaman
authors.initials: Y
authors.lastname: Mansouri
authors.affiliation: Department of Dermatology, Mount Sinai Hospital, 5 E 98th St, 5th Floor, New York, NY 10029-6574, USA. garygoldenbergmd@gmail.com.
authors.forename: Gary
authors.initials: G
authors.lastname: Goldenberg
mesh_terms: D000279:Administration, Cutaneous; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D006801:Humans; D062325:Intense Pulsed Light Therapy / Q000379:methods; D054025:Lasers, Dye / Q000627:therapeutic use*; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use; D010778:Photochemotherapy / Q000379:methods; D011788:Quality of Life; D012393:Rosacea / Q000188:drug therapy* / Q000601:surgery*; D013473:Sunscreening Agents / Q000008:administration & dosage; D016896:Treatment Outcome; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000316:Adrenergic alpha-Agonists; D003879:Dermatologic Agents; D013473:Sunscreening Agents; D014803:Vitamin B Complex; D009536:Niacinamide